A new molecule enters human testing: can ZE66-0205 prove safe?
NCT ID NCT07735728
First seen Jul 30, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This first-in-human trial tests the safety and tolerability of a single dose of the experimental drug ZE66-0205 in healthy adults aged 18 to 55. Researchers will also measure how the drug moves through the body and how it affects MALT1 levels in blood cells. Participants are randomly assigned to receive either ZE66-0205 or a placebo in gradually increasing doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called ZE66-0205
- What this could lead to
- If safe, this could pave the way for future studies of ZE66-0205 in diseases where MALT1 plays a role.
- What could go wrong
- This is a very early, small trial in healthy people — it is only checking safety and drug levels, not testing any disease benefit. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2031, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsing light on the scalp boost brain performance?
- Can heavy water reveal how the liver makes fat?
- Which bridge exercise fires up your muscles most? a study investigates
- Reading DNA clues: a blood test that could sniff out lung cancer
- Blood flow restriction may change how hamstrings use oxygen during exercise
- Brain scans reveal how experimental drug LG-0317 targets serotonin transporters